Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Assignment history

Inventors

Robert D. Gordon (Veloxis Pharmaceuticals Inc.)
Per Holm (Veloxis Pharmaceuticals Inc.)
Anne-Marie Lademann (Veloxis Pharmaceuticals Inc.)
Tomas Norling (Veloxis Pharmaceuticals Inc.)

All inventors were employed by Veloxis Pharmaceuticals Inc. at the time of filing. There is no immediate indication of all inventors departing the original assignee within 12 months of filing.

Original assignee

Veloxis Pharmaceuticals Inc. is the original assignee. Veloxis Pharmaceuticals Inc. is a pharmaceutical company that develops and commercializes tacrolimus for transplant patients. Their primary line of business is focused on immunosuppressive treatments. The company is currently operating and markets Envarsus XR (tacrolimus extended-release tablets), which embodies the claims of this patent.

Assignment timeline

The USPTO Patent Assignment Search was consulted on June 1, 2026, for patent US12083103. The search returned no recorded assignments for this patent number. This indicates that the original assignee, Veloxis Pharmaceuticals Inc., likely still holds ownership of the patent.

Timeline diagram

timeline
    title Ownership of US 12083103
    2021 : Filed by Veloxis Pharmaceuticals Inc.
    2024 : Issued to Veloxis Pharmaceuticals Inc.

NPE / troll-pattern signals

Shell-entity transfer — not present
Known asserter in the chain — not present
Repeat correspondent across the chain — not present (no assignments recorded)
Cascading transfers — not present (no assignments recorded)
Pre-litigation transfer — not present (no assignments recorded)
Bankruptcy fire-sale — not present
Privateering — not present
Defensive aggregator (anti-NPE) — not present

Verdict

Operating-company assertion

The patent currently remains with the original assignee, Veloxis Pharmaceuticals Inc., which markets a product (Envarsus XR) embodying the claims. The ongoing litigation in the Delaware District Court (Case Numbers 1:24-cv-00726, 1:24-cv-00784, and 1:26-cv-00467) indicates assertion against generic drug manufacturers, which is typical behavior for an operating company defending its market.

USPTO Assignment Center Search for US12083103